Key result
ERASE trial tests non-inferiority of robotic-assisted versus manual cerebral angiography for clinical success.
Why the study?
Manual cerebral angiography has inherent limitations, and existing robotic-assisted systems face challenges including limited compatibility, lengthy setup times, and a lack of high-quality real-world evidence.
Is robotic-assisted cerebral angiography using the YDHB-NS01 Ver 2.0 system non-inferior to conventional manual cerebral angiography in achieving clinical success without procedure-related serious adverse events in patients with suspected head and neck vascular lesions?
RCT (n=450)
Open-label with blinded endpoint (PROBE)
Central randomization via interactive web response system (IWRS), stratified by study centers (1:1 ratio)
Yes
Is robotic-assisted cerebral angiography using the YDHB-NS01 Ver 2.0 system non-inferior to conventional manual cerebral angiography in achieving clinical success without procedure-related serious adverse events in patients with suspected head and neck vascular lesions?
Answers are grounded in this paper and cite their sources.
This study protocol outlines a multicenter randomized controlled trial designed to evaluate the non-inferiority, clinical efficacy, and safety of the YDHB-NS01 Ver 2.0 robotic-assisted system compared to manual techniques for diagnostic cerebral angiography.
Neurointerventional therapy is a cornerstone in managing head and neck vascular disorders, with cerebral angiography serving as its fundamental diagnostic and therapeutic backbone. However, manual cerebral angiography is associated with several inherent limitations. While existing robotic-assisted systems have shown promise in mitigating some of these issues, they face challenges such as limited compatibility, lengthy setup times, and a lack of high-quality real-world evidence. The ERASE trial is a multicenter, prospective, randomized controlled trial (RCT). A total of 660 eligible patients will be enrolled from seven comprehensive stroke centers in China and randomized 1:1 to either the robotic-assisted group or the control group. Both groups use the Seldinger technique for femoral/radial artery access. Operators undergo standardized training on the robotic system. The trial adopts a prospective randomized open-label blinded endpoint (PROBE) design, with all imaging endpoints adjudicated via blinded review by an independent imaging core laboratory. All patients are followed up at baseline, end of surgery, 24 h postoperatively, and 7 days post-discharge. The primary efficacy outcome is the clinical success rate. The primary safety outcome is the incidence of perioperative/postoperative complications (e.g., vascular perforation, dissection, pseudoaneurysm), serious adverse events, and device malfunctions. Secondary outcomes include technical failure rate, overall procedural time, pre-puncture setup time, mean catheterization time per target vessel, super-selective technique success rate, DSA fluoroscopy time, participant radiation dose, primary operator radiation dose, contrast agent volume and instrument performance evaluation. A key safety endpoint is the rate of new asymptomatic cerebral infarctions detected via postoperative brain MRI-diffusion-weighted imaging. As the RCT focusing on the YDHB-NS01 Ver 2.0 system, the ERASE trial addresses critical unmet needs in neurointerventional practice and will generate high-quality evidence for robotic-assisted cerebral angiography. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT07182188. TRIAL REGISTRATION DATE: 2025-09-18.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) conducted an RCT in Suspected head and neck vascular lesions requiring cerebral angiography (n=450). YDHB-NS01 Ver 2.0 endovascular robotic-assisted system for cerebral angiography vs. Manual cerebral angiography was evaluated on Clinical success rate (clear visualization of all pre-specified target vessels without significant imaging artifacts and no procedure-related serious adverse events intraoperatively or within 24 hours post-procedure). The ERASE trial protocol evaluates the non-inferiority of the YDHB-NS01 Ver 2.0 robotic system versus manual cerebral angiography for clinical success in 450 patients.
Synapse has enriched 10 related papers. Consider them for comparative context: